VAP - Ventilator Associated Pneumonia
Conditions
Keywords
VAP - Ventilator Associated Pneumonia, Sepsis, Lung Infection, Broncho-alveolar Lavage, ICU
Brief summary
objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils
Interventions
None listed
Sponsors
BioMérieux
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All the following criteria * Age 18 years or greater * Severe ICU patients hospitalized for one of the above diseases: * Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (\>18 mg/dL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20) * Severe trauma (level I and II), Injury Severity Score ≥ 25 OR * Burn with TBSA over 20% * NAD \> 0.1 µg/kg/min * At least 2 SOFA criteria ≥ 2 points
Exclusion criteria
* Aspiration pneumonia * Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.) * COPD * Smoke inhalation in burn patients * Participation in an intervention study * Pregnant or breastfeeding women * Immunocompromised patients, defined as * patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease * hematologic malignancies * solid organ transplantation * HIV infection with or without AIDS * treatment with corticosteroids (\> 3 months at any dosage or ≥ 1 mg/kg prednisone equivalent per day for \> 7 day) * treatment with other immunosuppressive drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| immune cells patterns in VAP | before and at time of VAP diagnosis | The primary endpoint will be to describe and compare the distribution of immune cells within the lung and the blood before VAP diagnosis (VAP prediction) and at the time of VAP diagnosis. |
Countries
France
Contacts
Primary ContactJean-François LLITJOS
Backup ContactMarie-Angelique CAZALIS
Outcome results
None listed